MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that pre-clinical data on OSI-906, an orally active, potent and selective inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), were featured as part of a media program during the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held October 22-26, 2007 in San Francisco, CA. OSI presented data that support the clinical development of OSI-906 for the treatment of human cancers as a single agent and in combination with other molecular targeted agents, including Tarceva® (erlotinib).
